Eppendorf striving to ensure all labs are smart, safe, and stress-free, with Eppendorf Advantage
A range of best-in-class solutions that drive productivity in the laboratory.
Eppendorf has announced the latest Advantage promotion period, until 31 December 2016, on a range of best-in-class solutions that drive productivity in the laboratory. With sample safety, intuitive functionality, and reliability in mind, Eppendorf offers solutions that support a smart, safe, and stress-free environment for researchers across the life sciences industry.
For many research labs, handling hazardous liquids, such as foaming, viscous, volatile, dense, corrosive or hazardous solutions, can be challenging, particularly when the properties of these liquids can affect, and impair, the accuracy and reproducibility of results. The Advantage range includes, the ergonomically designed Multipette M4, with positive displacement, and Combitips advanced, which can eliminate these associated challenges. The Multipette M4 offers a unique volume range, 1 µL–10 µL, and can accommodate 9 Combitips advanced sizes from 0.1 to 50 mL. In addition, automatic Combitip recognition, combined with the ability to conduct 100 dispensing steps, without the need for refilling the tip, ensures fast, precise, and contamination-free dispensing.
Steve Dey, Marketing Director, Eppendorf UK Limited commented: “We at Eppendorf are always striving to be the expert partner in life science laboratories. As one of the industry's technology leaders, we have set industry standards time and again over past decades and always look to the future to contribute to making repetitive laboratory workflows simple, precise, safe and efficient. Eppendorf Advantage is an opportunity for those working across life sciences to optimise their laboratory productivity.”
Additional solutions for researchers and technicians to take advantage of include the Eppendorf ThermoMixer C; with quick and easy-to-exchange SmartBlocks for common lab vessel and plate formats from 5 µL to 50 µL, it is ideally suited to applications such as plasmid/RNA/DNA purification, cDNA synthesis, bacterial growth and lysis reactions at 100 °C. Researchers can expect consistently dependable and reproducible assay results due to outstanding mixing performance, with 2DMix-Control, and exceptional temperature regulation, meaning samples can be simultaneously mixed and incubated.
Until 31 December, the 24-place Centrifuge 5424, and refrigerated 5424 R, will also be on offer, as part of a Special Value Pack which also includes an 18-place Eppendorf Kit rotor, giving researchers access to state-of-the-art cooling technology, for maximum sample protection. Similarly, researchers can purchase the Innova 44, and 44R incubator shakers, which offer broad temperature capabilities and varying shaking speeds for culturing a wide variety of cell types in flasks up to 5 L.
Researchers and technicians will also be able to purchase the perfect tools for methods in nucleic acids, protein, and turbidity measurements: the Eppendorf BioPhotometer D30 records at fixed wavelengths, clearly processes data volume, and makes evaluating results fast, and simple, whilst the Eppendorf µCuvette G1.0 is ideal for microvolume measurements of highly concentrated samples without prior dilution.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.